A detailed history of Cubist Systematic Strategies, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 52,523 shares of SAGE stock, worth $566,197. This represents 0.01% of its overall portfolio holdings.

Number of Shares
52,523
Previous 22,810 130.26%
Holding current value
$566,197
Previous $494,000 99.19%
% of portfolio
0.01%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $553,256 - $800,765
29,713 Added 130.26%
52,523 $984,000
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $390,051 - $507,750
22,810 New
22,810 $494,000
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $336,663 - $493,110
-8,282 Reduced 34.01%
16,071 $755,000
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $147,924 - $184,836
3,969 Added 19.47%
24,353 $1.02 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $272,090 - $368,504
-8,450 Reduced 29.31%
20,384 $777,000
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $1.68 Million - $2.25 Million
-52,089 Reduced 64.37%
28,834 $1.13 Million
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $535,346 - $739,019
19,453 Added 31.65%
80,923 $2.61 Million
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $1.22 Million - $1.82 Million
-39,760 Reduced 39.28%
61,470 $2.04 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $413,070 - $525,088
-11,146 Reduced 9.92%
101,230 $4.31 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $3.22 Million - $4.59 Million
80,036 Added 247.48%
112,376 $4.98 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $498,859 - $720,746
9,090 Added 39.1%
32,340 $1.84 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $1.64 Million - $2.25 Million
23,250 New
23,250 $1.74 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $2.42 Million - $3.69 Million
-41,459 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$41.13 - $62.45 $122,567 - $186,101
2,980 Added 7.74%
41,459 $2.53 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $1.08 Million - $1.79 Million
-41,507 Reduced 51.89%
38,479 $1.6 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $192,516 - $568,640
7,362 Added 10.14%
79,986 $2.3 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $4.17 Million - $10.7 Million
69,286 Added 2075.67%
72,624 $5.24 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $77,580 - $105,047
553 Added 19.86%
3,338 $468,000
Q2 2019

Aug 14, 2019

SELL
$157.85 - $183.09 $740,947 - $859,424
-4,694 Reduced 62.76%
2,785 $510,000
Q1 2019

May 15, 2019

BUY
$89.33 - $163.65 $132,476 - $242,692
1,483 Added 24.73%
7,479 $1.19 Million
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $469,598 - $800,678
-5,731 Reduced 48.87%
5,996 $574,000
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $8.89 Million - $10.9 Million
-64,383 Reduced 84.59%
11,727 $1.66 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $10.7 Million - $13.4 Million
76,110 New
76,110 $11.9 Million
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $53,252 - $67,315
-350 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $42,625 - $117,472
-702 Reduced 66.73%
350 $58,000
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $64,592 - $93,123
1,052
1,052 $66,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.